Arcutis Biotherapeutics is expected to report Q3 2026 revenue of $78.20 million and earnings per share of $0.17, while the stock trades at $14.12 against a $21.00 average analyst target. The primary focus for investors remains the commercial trajectory of ZORYVE (roflumilast), specifically its sales performance following its recent launch into the atopic dermatitis market.
Analysts are looking for evidence that prescription volume growth is successfully offsetting gross-to-net pricing pressures common in the dermatology space. Management’s guidance on the timeline for reaching cash flow break-even will also be critical as the company scales its commercial infrastructure.